{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Malignant+Solid+Neoplasm&page=8", "query": { "condition": "Recurrent Malignant Solid Neoplasm", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 241, "total_pages": 25, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Malignant+Solid+Neoplasm&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Malignant+Solid+Neoplasm&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T00:04:08.986Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03725436", "title": "ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Estrogen Receptor Positive", "HER2/Neu Negative", "Metastatic Malignant Solid Neoplasm", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Recurrent Breast Carcinoma", "TP53 wt Allele", "Unresectable Malignant Solid Neoplasm" ], "interventions": [ { "name": "MDM2/MDMX Inhibitor ALRN-6924", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2019-01-24", "completion_date": "2026-03-11", "has_results": false, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-10-21T00:04:08.986Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03725436" }, { "nct_id": "NCT02323880", "title": "Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Glioma", "Recurrent Brain Neoplasm", "Recurrent Childhood Central Nervous System Neoplasm", "Recurrent Childhood Glioblastoma", "Recurrent Lymphoma", "Recurrent Malignant Solid Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Primary Central Nervous System Neoplasm", "WHO Grade 3 Glioma" ], "interventions": [ { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Selinexor", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 59, "start_date": "2015-10-30", "completion_date": "2024-12-31", "has_results": true, "last_update_posted_date": "2025-01-14", "last_synced_at": "2026-10-21T00:04:08.986Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02323880" }, { "nct_id": "NCT00892736", "title": "Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Basal-Like Breast Carcinoma", "BRCA1 Mutation Carrier", "BRCA2 Mutation Carrier", "Breast Carcinoma", "Estrogen Receptor Negative", "HER2/Neu Negative", "Hereditary Breast and Ovarian Cancer Syndrome", "Ovarian Carcinoma", "Pancreatic Carcinoma", "Progesterone Receptor Negative", "Prostate Carcinoma", "Recurrent Breast Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Solid Neoplasm", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Veliparib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 98, "start_date": "2009-04-20", "completion_date": "2017-05-19", "has_results": false, "last_update_posted_date": "2018-06-29", "last_synced_at": "2026-10-21T00:04:08.986Z", "location_count": 7, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "South Pasadena", "state": "California" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00892736" }, { "nct_id": "NCT03507452", "title": "First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Recurrent Malignant Pleural Epithelioid Mesothelioma", "Advanced Recurrent Malignant Peritoneal Epithelioid Mesothelioma", "Advanced Recurrent Serous Ovarian Cancer", "Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated)" ], "interventions": [ { "name": "BAY2287411", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2018-06-13", "completion_date": "2022-03-29", "has_results": false, "last_update_posted_date": "2023-03-20", "last_synced_at": "2026-10-21T00:04:08.986Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Houston, Texas", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03507452" }, { "nct_id": "NCT02780804", "title": "Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain Stem Neoplasm", "Pineal Region Neoplasm", "Recurrent Lymphoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Primary Central Nervous System Neoplasm", "Recurrent Visual Pathway Glioma", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Primary Central Nervous System Neoplasm", "Refractory Visual Pathway Glioma" ], "interventions": [ { "name": "Entinostat", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 21, "start_date": "2017-01-06", "completion_date": "2021-09-30", "has_results": true, "last_update_posted_date": "2023-10-17", "last_synced_at": "2026-10-21T00:04:08.986Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02780804" }, { "nct_id": "NCT01050504", "title": "Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Localized Renal Pelvis and Ureter Urothelial Carcinoma", "Malignant Solid Neoplasm", "Metastatic Malignant Neoplasm in the Bone", "Metastatic Malignant Neoplasm in the Soft Tissues", "Metastatic Renal Pelvis and Ureter Urothelial Carcinoma", "Recurrent Bladder Carcinoma", "Recurrent Prostate Carcinoma", "Recurrent Renal Pelvis and Ureter Urothelial Carcinoma", "Stage IV Bladder Cancer AJCC v7", "Stage IV Bladder Urothelial Carcinoma AJCC v7", "Stage IV Prostate Cancer AJCC v7" ], "interventions": [ { "name": "Cytology Specimen Collection Procedure", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1500, "start_date": "2009-08", "completion_date": "2029-01-31", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-10-21T00:04:08.986Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01050504" }, { "nct_id": "NCT00083213", "title": "Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "ziv-aflibercept", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 25, "start_date": "2004-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-06-03", "last_synced_at": "2026-10-21T00:04:08.986Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00083213" }, { "nct_id": "NCT00237627", "title": "Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Ovarian Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "PS-341", "type": "DRUG" }, { "name": "Doxil", "type": "DRUG" }, { "name": "Velcade", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2001-05", "completion_date": "2010-01", "has_results": false, "last_update_posted_date": "2012-05-18", "last_synced_at": "2026-10-21T00:04:08.986Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00237627" }, { "nct_id": "NCT05722288", "title": "Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Localized Prostate Carcinoma", "Locally Advanced Cervical Carcinoma", "Locally Advanced Rectal Carcinoma", "Malignant Solid Neoplasm", "Recurrent Prostate Carcinoma", "Stage I Prostate Cancer AJCC v8", "Stage IB Cervical Cancer FIGO 2018", "Stage IB2 Cervical Cancer FIGO 2018", "Stage II Prostate Cancer AJCC v8", "Stage II Rectal Cancer AJCC v8", "Stage IIA Cervical Cancer FIGO 2018", "Stage IIB Cervical Cancer FIGO 2018", "Stage III Prostate Cancer AJCC v8", "Stage III Rectal Cancer AJCC v8", "Stage IIIA Cervical Cancer FIGO 2018", "Stage IIIB Cervical Cancer FIGO 2018", "Stage IIIC Cervical Cancer FIGO 2018", "Stage IVA Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Informational Intervention", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Short-Term Fasting", "type": "BEHAVIORAL" } ], "intervention_types": [ "PROCEDURE", "OTHER", "BEHAVIORAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2023-03-23", "completion_date": "2027-07-05", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-21T00:04:08.986Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05722288" }, { "nct_id": "NCT05985161", "title": "A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Wilms Tumor", "Rhabdoid Tumor", "Malignant Peripheral Nerve Sheath Tumors", "MPNST", "Nephroblastoma", "XPO1 Gene Mutation", "Solid Tumor" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": null, "sex": "ALL", "summary": "12 Months and older" }, "enrollment_count": 45, "start_date": "2023-08-01", "completion_date": "2029-08-01", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-21T00:04:08.986Z", "location_count": 16, "location_summary": "Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05985161" } ] }